Focus on musculoskeletal health in women with bleeding disorders

1 Chapple ILC, Genco R et al. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontology 2013; 40 (suppl 14): 106–112. doi: 10.1902/jop.2013.1340011. ChappleILC GencoR Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases J Clin Periodontology 2013 40 suppl 14 106 112 10.1902/jop.2013.1340011 23631572 Open DOISearch in Google Scholar

2 Epping L, Miesbach W, Nickles K, Eickholz P. Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One 2018; 13(1): e0191291. doi: 10.1371/journal/pone.0191291. EppingL MiesbachW NicklesK EickholzP Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One 2018 13 1 e0191291 10.1371/journal/pone.0191291 Open DOISearch in Google Scholar

3 Brewer A, Correa ME, on behalf of the World Federation of Hemophilia Dental Committee. Guidelines for dental treatment of patients with inherited bleeding disorders. Treatment of Haemophilia, no. 40, May 2006. Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022). BrewerA CorreaME on behalf of the World Federation of Hemophilia Dental Committee Guidelines for dental treatment of patients with inherited bleeding disorders Treatment of Haemophilia 40 May 2006 Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022). Search in Google Scholar

4 Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5(1): 301–325. doi: 10.1182/bloodadvances.2020003264. ConnellNT FloodVH Brignardello-PetersenR ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv 2021 5 1 301 325 10.1182/bloodadvances.2020003264 780532633570647 Open DOISearch in Google Scholar

5 Poveda Roda R, Bagan JV, Díaz Fernández, et al. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal 2007; 12(4): E292–8. Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022). Poveda RodaR BaganJV Díaz Fernández Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors Med Oral Patol Oral Cir Bucal 2007 12 4 E292 8 Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022). Search in Google Scholar

6 Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65(2): 615–621. Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022). GrushkaM EpsteinJB GorskyM Burning mouth syndrome Am Fam Physician 2002 65 2 615 621 Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022). Search in Google Scholar

7 Dahiya P, Kamal R, Kumar M, Gupta R, Chaudhary K. Burning mouth syndrome and menopause. Int J Prev Med 2013; 4(1): 15–20. DahiyaP KamalR KumarM GuptaR ChaudharyK Burning mouth syndrome and menopause Int J Prev Med 2013 4 1 15 20 Search in Google Scholar

8 Ślebioda Z, Szponar E. Burning mouth syndrome – a common dental problem in perimenopausal women. Prz Menopauzalny 2014; 13 (3): 198–202. doi: 10.5114/pm.2014.43825. ŚlebiodaZ SzponarE Burning mouth syndrome – a common dental problem in perimenopausal women Prz Menopauzalny 2014 13 3 198 202 10.5114/pm.2014.43825 452036326327855 Open DOISearch in Google Scholar

9 Osooli M, Donfield SM, Carlsson KS et al. Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years. Haemophilia 2019; 25(5): 845–850. doi: 10.1111/hae.13831. OsooliM DonfieldSM CarlssonKS Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years Haemophilia 2019 25 5 845 850 10.1111/hae.13831 31411798 Open DOISearch in Google Scholar

10 van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost 2018; 118(10): 1690–1700. doi: 10.1055/s-0038-1670704. van GalenKPM TimmerM de KleijnP Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis Thromb Haemost 2018 118 10 1690 1700 10.1055/s-0038-1670704 30273954 Open DOISearch in Google Scholar

11 Négrier C, Mahlangu J, Lehle M, et al. Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study. Blood 2021; 138(1): 343. doi: 10.1182/blood-2021-146009. NégrierC MahlanguJ LehleM Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study Blood 2021 138 1 343 10.1182/blood-2021-146009 Open DOISearch in Google Scholar

12 Hermans C, Négrier C, Lehle M, et al. Emicizumab prophylaxis for the treatment of people with moderate or mild haemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study [abstract]. ISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022). HermansC NégrierC LehleM Emicizumab prophylaxis for the treatment of people with moderate or mild haemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study [abstract] ISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022). Search in Google Scholar

13 National Library of Medicine (US). Emicizumab for severe von Willebrand disease (VWD) and VWD/haemophilia A (BCDI-XII). 15 August 2022-. Identifier: NCT05500807. Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022). National Library of Medicine (US) Emicizumab for severe von Willebrand disease (VWD) and VWD/haemophilia A (BCDI-XII). 15 August 2022-. Identifier: NCT05500807 Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022). Search in Google Scholar

14 Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: 10.1111/14046. SrivastavaA SantagostinoE DougallA WFH Guidelines for the Management of Hemophilia, 3rd edition Haemophilia 2020 26 Suppl 6 1 158 10.1111/14046 Open DOISearch in Google Scholar

15 de Kleijn P, Duport G, Jansone K, et al; European Haemophilia Consortium and EAHAD Physiotherapy Committee. European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients. Haemophilia 2022 May 4. doi: 10.1111/hae.14566. Online ahead of print. de KleijnP DuportG JansoneK European Haemophilia Consortium and EAHAD Physiotherapy Committee European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients Haemophilia 2022 May 4 10.1111/hae.14566 Online ahead of print. 35506491 Open DOISearch in Google Scholar

16 Citla-Sridhar D, Sidonio RF, Ahuja SP. Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. Haemophilia 2022; 28(4): 671–678. doi: 10.1111/hae.14565. Citla-SridharD SidonioRF AhujaSP Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis Haemophilia 2022 28 4 671 678 10.1111/hae.14565 35416396 Open DOISearch in Google Scholar